Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management ...

Edesa Biotech has announced its participation in upcoming conferences, including BIO-Europe in Vienna and the LSX Investival Showcase in London. This participation highlights Edesa’s ongoing efforts ...

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (KNE:CA) (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its ...

A webcast replay of the discussion will be available from the Investors section of the company’s website at www.iobiotech.com for 30 days. A webcast replay of the discussion will be available from the ...

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, ...

MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an update. On October 27, 2025, MAIA Biotechnology announced its participation in the 2025 ...

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple international conferences, highlighting its focus on ...

“Clinical conferences are an opportunity for Kane to reinforce our innovation in wound care,” said Dr. Robert Huizinga, Interim CEO. “These presentations are an expansion of our market support plan ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. PALO ALTO, Calif. — At an annual meeting usually focused on the industry’s future, ...

Cylembio ® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and ...